Aldeyra Therapeutics Inc
NASDAQ:ALDX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Aldeyra Therapeutics Inc
Research & Development
Aldeyra Therapeutics Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Aldeyra Therapeutics Inc
NASDAQ:ALDX
|
Research & Development
-$25.7m
|
CAGR 3-Years
18%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-13%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$9.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
Research & Development
-$523m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-31%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
Aldeyra Therapeutics Inc
Glance View
Aldeyra Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Lexington, Massachusetts and currently employs 12 full-time employees. The company went IPO on 2014-05-02. The firm's lead product candidate, reproxalap, is a treatment in late-stage development for dry eye disease (DED) and allergic conjunctivitis (AC). The company has additional product candidates in development for proliferative vitreoretinopathy (PVR), primary vitreoretinal lymphoma (PVRL) and other retinal diseases, autoimmune disease, and cancer. The firm's product development pipeline is focused on immune-mediated ocular diseases and select systemic diseases and encompasses two biological mechanisms of action: reactive aldehyde species (RASP) modulation and dihydrofolate reductase inhibition. The immunological activity of its product candidates generally leads to diminished levels of pathological inflammation through down-regulation of immune cell activation or proliferation.
See Also
What is Aldeyra Therapeutics Inc's Research & Development?
Research & Development
-25.7m
USD
Based on the financial report for Dec 31, 2025, Aldeyra Therapeutics Inc's Research & Development amounts to -25.7m USD.
What is Aldeyra Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-13%
Over the last year, the Research & Development growth was 47%. The average annual Research & Development growth rates for Aldeyra Therapeutics Inc have been 18% over the past three years , -1% over the past five years , and -13% over the past ten years .
